COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,731 Articles (22,502 medRxiv, 8,229 bioRxiv)

Most recent first Previous |  Page 1263: Articles 12621-12630  | Next

Automated ELISA on-chip for the detection of an-ti-SARS-CoV-2 antibodies
Gonzalez-Gonzalez, E., Garcia-Ramirez, R., Diaz Armas, G. G., Esparza, M., Aguilar-Avelar, C., Flores-Contreras, E. A., Rodriguez-Sanchez, I. P., Delgado-Balderas, J. R., Soto-Garcia, B., Araiz-Hernandez, D., Abarca-Blanco, M., Yee-de Leon, J. R., Velarde-Calvillo, L. P., Abarca-Blanco, A., Yee-de Leon, J. F.
10.1101/2021.08.05.21261664 — Posted: 2021-08-08
Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blinded, Randomised, Placebo-Controlled Phase 2 Trial
Hsieh, S.-M., Liu, M.-C., Chen, Y.-H., Lee, W.-S., Hwang, S.-J., Cheng, S.-H., Ko, W.-C., Hwang, K.-P., Wang, N.-C., Lee, Y.-L., Lin, Y.-L., Shih, S.-R., Huang, C.-G., Liao, C.-C., Liang, J.-J., Chang, C.-S., Chen, C., Lien, C. E., Tai, I.-C., Lin, T.-Y.
10.1101/2021.08.05.21261532 — Posted: 2021-08-08 Discussion: Onsite
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Li, M., Yang, J., Wang, L., Wu, Q., Wu, Z., Zheng, W., Wang, L., Lu, W., Deng, X., Peng, C., Han, B., Zhao, Y., Yu, H., Yin, W.
10.1101/2021.08.03.21261544 — Posted: 2021-08-08
SARS-CoV-2 Suppression and Early Closure of Bars and Restaurants : A Longitudinal Natural Experiment
Takaku, R., Yokoyama, I., Tabuchi, T., Fujiwara, T.
10.1101/2021.08.07.21261741 — Posted: 2021-08-08
VPS29 exerts opposing effects on endocytic viral entry
Poston, D., Weisblum, Y., Hobbs, A., Bieniasz, P. D.
10.1101/2021.08.06.455441 — Posted: 2021-08-08
MFDNN: Multi-channel feature deep neural network algorithm to identify Covid19 chest X-ray images
Pan, L., ji, b., wang, X., peng, s.
10.1101/2021.08.04.21261235 — Posted: 2021-08-08
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J., Corchado-Garcia, J., O'Horo, J. C., Virk, A., Swift, M. D., Halamka, J., Badley, A. D., Venkatakrishnan, A., Soundararajan, V.
10.1101/2021.08.06.21261707 — Posted: 2021-08-08 Discussion: Onsite
Green spaces, especially forest, linked to lower SARS-CoV-2 infection rates: A one-year nationwide study
Jiang, B., Yang, Y., Chen, L., Liu, X., Wu, X., Chen, B., Webster, C., Sullivan, W. C., Wang, J., Lu, Y.
10.1101/2021.08.04.21261420 — Posted: 2021-08-08
Breastfeeding Practices Among Mothers During COVID-19 in India
Akinola, A. A., Simon, N. H., Mohamed, N. A.
10.1101/2021.08.06.21261582 — Posted: 2021-08-08
SARS-CoV-2 Breakthrough Infections among the Healthcare Workers Post-Vaccination with ChAdOx1 nCoV-19 Vaccine in the South Indian State of Kerala.
Issac, A., Kochuparambil, J. J., Elizabeth, L.
10.1101/2021.08.07.21261587 — Posted: 2021-08-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).